Product information and disease descriptionPlace of product in therapyDisease description
Pathophysiology
8 evidence topics · 6 sources
Primary aldosteronism: renin-independent aldosterone production and volume expansion
Continuum of renin-independent aldosterone production across blood pressure categories
“Participants with normotension (n = 289), stage 1 hypertension (n = 115), stage 2 hypertension (n = 203), and resistant hypertension (n = 408).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Every blood pressure category had a continuum of renin-independent aldosterone production, where greater severity of production was associated with higher blood pressure, kaliuresis, and lower serum potassium levels.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean adjusted levels of urinary aldosterone were 6.5 μg/24 h (95% CI, 5.2 to 7.7 μg/24 h) in normotension, 7.3 μg/24 h (CI, 5.6 to 8.9 μg/24 h) in stage 1 hypertension, 9.5 μg/24 h (CI, 8.2 to 10.8 μg/24 h) in stage 2 hypertension, and 14.6 μg/24 h (CI, 12.9 to 16.2 μg/24 h) in resistant hypertension” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Beyond this categorical definition of primary aldosteronism, there is a prevalent continuum of renin-independent aldosterone production that parallels the severity of hypertension.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Mineralocorticoid receptor activation and target organ injury
“This renin-independent aldosterone production can cause hypertension, but interactions with the mineralocorticoid receptor also cause hypokalemia and increased risk for adverse cardiovascular outcomes” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Chronic renin-angiotensin-aldosterone system activation and excess aldosterone exert detrimental effects on the heart and the kidneys via contributing to inflammation, fibrosis, and dysfunction in the myocardium, vasculature, and the kidneys.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“These effects are purported to be through genomic mineralocorticoid receptor (MR)-mediated, nongenomic MR-dependent, and nongenomic non-MR dependent actions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Because both hyperkalemia and excess aldosterone are associated with progression of CKD and HF, and MRA therapy is associated with elevations in aldosterone levels, patients on MRA therapy may remain at a high residual risk for poor outcomes even on MRA therapy.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Aldosterone excess and intravascular volume expansion in resistant hypertension
“Consecutive subjects with resistant hypertension (RHTN) (n=279) and controls (n=53) were prospectively evaluated for plasma aldosterone (PAC), plasma renin activity (PRA), aldosterone-renin ratio (ARR), brain natriuretic peptide (BNP), atrial natriuretic peptide (ANP), 24-hr urinary aldosterone (UAldo), cortisol (UCort), sodium (UNa) and potassium (UK) on their routine diet.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“PAC (13±0.5 vs. 8.4±0.7 ng/dl, p=0.0005), ARR (22±1.7 vs. 6±0.7, p < 0.0001), UAldo (13±0.6 vs. 9.7±0.9 μg/24hr, p=0.02), BNP (37.2±3.1 vs. 22.5±3.4 pg/ml, p=0.007) and ANP (95.9±5.8 vs. 54.8±4.9 pg/ml, p=0.001) were higher, PRA (2.3±0.2 vs. 3.8±0.9 ng/ml/hr, p=0.02) and serum potassium (3.9±0.03 vs. 4.3±0.06 mEq/L, p < 0.0001) were lower in patients with RHTN compared to controls.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These findings indicate that aldosterone levels are higher and there is evidence of intravascular volume expansion (higher BNP and ANP levels) in patients with resistant hypertension compared to controls.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Renin suppression and sodium retention in resistant hypertension
“and suppressed circulating renin levels (≈60% of those with RH have suppressed renin levels).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In general, RH is characterized by exquisite salt sensitivity of BP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Home systolic blood pressure reduction by spironolactone was predicted by ARR (r2=0·13, p<0·0001) and plasma renin (r2=0·11, p=0·00024).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thus, 31 (25% [95% CI 17–33]) of 126 patients were deemed to have inappropriately high aldosterone concentrations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thoracic fluid content was reduced by 6·8% from baseline (95% CI 4·0 to 8·8; p<0·0001) with spironolactone, but not other treatments.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Our results suggest that resistant hypertension is commonly a salt-retaining state, most likely due to inappropriate aldosterone secretion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mineralocorticoid receptor blockade by spironolactone overcomes the salt retention and resistance of hypertension to treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Obesity: visceral adiposity and mineralocorticoid activity
“Visceral adiposity in particular plays a fundamental role in causing high BP through a variety of mechanisms culminating in enhanced salt sensitivity, vascular dysfunction, and activation of the sympathetic nervous system and renin-angiotensin system.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mounting evidence further supports the importance of heightened mineralocorticoid activity in RH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Chronic kidney disease: impaired sodium excretion and volume expansion
“CKD is both a cause and a complication of poorly controlled hypertension.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Reduced kidney function results in impaired salt excretion, overactivation of the renin-angiotensin-aldosterone system, increased sympathetic nervous system activity, and altered medication efficacy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment resistance in patients with CKD is undoubtedly related in large part to increased sodium and fluid retention and consequential intravascular volume expansion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Obstructive sleep apnea: fluid retention and aldosterone excess
“OSA is extremely common in patients with RH, with prevalence rates as high as 70% to 90%, and when present, OSA is often severe.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The high occurrence of OSA in patients with RH has been attributed to increased fluid retention and accompanying upper airway edema, as suggested by studies positively relating the presence and severity of OSA to aldosterone excess and high dietary sodium intake.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The role of aldosterone in promoting OSA is additionally supported by studies demonstrating that mineralocorticoid receptor antagonists reduce the severity of OSA in patients with RH.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote